Bullfrog AI enters commercial agreement with Lieber Institute to commercialize AI-derived brain data products

BullFrog AI Holdings, Inc.

Entered commercial agreement with Lieber Institute for Brain Development to commercialize AI/ML products from LIBD brain data.
BFAI granted exclusive worldwide license to develop, sell Licensed Products in drug development field (therapeutic, target ID, patient selection).
BFAI to pay LIBD royalty on Net Sales (rates redacted); exclusivity ends if no First Commercial Sale within 2 years of listing.
LIBD may change license to non-exclusive after 3 years from First Commercial Sale, adjusting royalty rate.
LIBD receives Licensed Products free for internal research; if LIBD commercializes, pays BFAI 70% of Net Sales.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BullFrog AI Holdings, Inc. entered into Commercial Agreement with Lieber Institute for Brain Development (effective 2023-10-16).

Action: entry
Counterparty: Lieber Institute for Brain Development
Effective: 2023-10-16

Exact text from the filing

Effective October 16, 2023, Bullfrog AI Holdings, Inc. (the “Company”) entered a Commercial Agreement (the “Agreement”) with the Lieber Institute for Brain Development (LDB) engaging in the development and commercialization of AI and machine learning solutions to advance medicine and improve human health.

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

BullFrog AI Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-037840

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.